NO311920B1 - Xantinderivater som adenosin-A1-reseptorantagonister - Google Patents

Xantinderivater som adenosin-A1-reseptorantagonister Download PDF

Info

Publication number
NO311920B1
NO311920B1 NO19953353A NO953353A NO311920B1 NO 311920 B1 NO311920 B1 NO 311920B1 NO 19953353 A NO19953353 A NO 19953353A NO 953353 A NO953353 A NO 953353A NO 311920 B1 NO311920 B1 NO 311920B1
Authority
NO
Norway
Prior art keywords
dipropyl
purine
dihydro
dione
give
Prior art date
Application number
NO19953353A
Other languages
English (en)
Norwegian (no)
Other versions
NO953353L (no
NO953353D0 (no
Inventor
Janice Mary Hitchcock
Stephen Martin Sorenson
Mark William Dudley
Norton Paul Peet
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NO953353L publication Critical patent/NO953353L/no
Publication of NO953353D0 publication Critical patent/NO953353D0/no
Publication of NO311920B1 publication Critical patent/NO311920B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19953353A 1993-02-26 1995-08-25 Xantinderivater som adenosin-A1-reseptorantagonister NO311920B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2350193A 1993-02-26 1993-02-26
PCT/US1994/001009 WO1994019349A1 (en) 1993-02-26 1994-01-27 Xanthine derivatives as adenosine a1 receptor antagonists

Publications (3)

Publication Number Publication Date
NO953353L NO953353L (no) 1995-08-25
NO953353D0 NO953353D0 (no) 1995-08-25
NO311920B1 true NO311920B1 (no) 2002-02-18

Family

ID=21815459

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19953353A NO311920B1 (no) 1993-02-26 1995-08-25 Xantinderivater som adenosin-A1-reseptorantagonister

Country Status (19)

Country Link
US (1) US5840729A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0686155B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH08512281A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100315898B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1041418C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE169019T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU680241B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2155130C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69412073T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0686155T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2120025T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT72677A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL108750A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9401406A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO311920B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ262984A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW261532B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1994019349A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA941176B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0972525A4 (en) * 1997-03-18 2000-11-29 Fujisawa Pharmaceutical Co PREVENTIVE AND HEALING AGENTS AGAINST HYPERPHOSPHATEMIA
TR200003513T2 (tr) 1998-06-02 2001-06-21 Osi Pharmaceuticals, Inc. Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
CA2468673C (en) 2001-11-30 2011-01-25 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1 and a3 receptors and uses thereof
US6916804B2 (en) 2001-12-20 2005-07-12 Osi Pharmaceuticals, Inc. Pyrimidine A2b selective antagonist compounds, their synthesis and use
AU2003239472A1 (en) * 2002-05-15 2003-12-02 Genzyme Corporation Synthesis of benzonitriles and benzimidates
WO2004086047A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1)
EP1709966A4 (en) * 2003-12-09 2009-04-29 PREVENTIVE AND / OR THERAPEUTIC AGENT FOR SEVERE CEREBRAL DYSFUNCTION
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
JPH0455150A (ja) * 1990-06-22 1992-02-21 Takata Kk 助手席用エアバッグ装置
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5087827A (en) * 1991-02-11 1992-02-11 Tektronix, Inc. Variable voltage transition circuit
US5208240A (en) * 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
DE69412073T2 (de) 1999-02-18
US5840729A (en) 1998-11-24
KR100315898B1 (ko) 2002-02-28
CN1118599A (zh) 1996-03-13
NZ262984A (en) 1997-05-26
ATE169019T1 (de) 1998-08-15
EP0686155B1 (en) 1998-07-29
ES2120025T3 (es) 1998-10-16
NO953353L (no) 1995-08-25
TW261532B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-11-01
AU6296894A (en) 1994-09-14
IL108750A (en) 2000-09-28
EP0686155A1 (en) 1995-12-13
WO1994019349A1 (en) 1994-09-01
JPH08512281A (ja) 1996-12-24
CN1041418C (zh) 1998-12-30
HU9502495D0 (en) 1995-10-30
MX9401406A (es) 1994-08-31
DK0686155T3 (da) 1999-02-01
NO953353D0 (no) 1995-08-25
ZA941176B (en) 1994-09-20
CA2155130A1 (en) 1994-09-01
CA2155130C (en) 1994-09-01
AU680241B2 (en) 1997-07-24
DE69412073D1 (de) 1998-09-03
IL108750A0 (en) 1994-05-30
HUT72677A (en) 1996-05-28

Similar Documents

Publication Publication Date Title
US6545000B1 (en) [1,2,4]triazolo[1,5-c]pyrimidine derivatives
US5212176A (en) R(+)-terazosin
DK169271B1 (da) 8-Phenylxanthinderivater, fremgansmåde til fremstilling heraf, farmaceutisk præparat indeholdende en sådan forbindelse, samt en sådan forbindelse til anvendelse til terapi
DE69123974T2 (de) Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen
AU2007227021B2 (en) Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
DE69721776T2 (de) Verbindungen mit antihypertensiven, cardioprotektiven, antiischämischen und antilipolytischen eigenschaften
US20070208040A1 (en) A2a adenosine receptor antagonists
NO312679B1 (no) N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat
NO311920B1 (no) Xantinderivater som adenosin-A1-reseptorantagonister
EP1347981B1 (en) Condensed purine derivatives as a 1 adenosine receptor antagonists
AU2002219977A1 (en) Condensed purine derivatives as A1 adenosine receptor antagonists
US5047534A (en) Selective adenosine receptor agents
TW200817401A (en) KW-3902 conjugates that do not cross the blood-brain barrier
JPH08509977A (ja) 選択的アデノシン受容体剤としての8−置換キサンチン類
HK1059927B (en) Condensed purine derivatives as a1 adenosine receptor antagonists
HK1038014A (en) (1,2,4) TRIAZOLO(1,5-c) PYRIMIDINE DERIVATIVES

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees